ArticleAJNR. American journal of neuroradiology2025
Repeatability and Reproducibility of Pseudocontinuous Arterial Spin-Labeling-Measured Brain Perfusion in Healthy Volunteers and Patients with Glioblastoma.
Article in AJNR. American journal of neuroradiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03922984 (A Prospective Study to Evaluate Quantitative Non-Contrast Perfusion Using Arterial Spin Labeled Magnetic Resonance), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective Study to Evaluate Quantitative Non-Contrast Perfusion Using Arterial Spin Labeled Magnetic Resonance (MR) Imaging for Assessment of Therapy Response in Glioblastoma
Who cites it
1 citing paper in PubMed.
- Magnetic resonance imaging-guided linear accelerator arterial spin labelling reveals dynamics of highly perfused non-enhancing glioblastoma during radiotherapy.Physics and imaging in radiation oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
background and purposeArterial spin-labeling (ASL) MRI has gained recognition as a quantitative perfusion imaging method for managing patients with brain tumors. Limited studies have so far investigated the reproducibility of ASL-derived perfusion in these patients. This study aimed to evaluate intrasession repeatability and intersession reproducibility of perfusion measurements using 3D pseudocontinuous ASL (pCASL) with TSE Cartesian acquisition with spiral profile reordering (TSE-CASPR) in healthy volunteers (HV) and patients with glioblastoma (GBM) at 3T and to compare them against 3D pCASL with gradient and spin echo (GRASE). MATERIALS AND
methodsThis prospective study (NCT03922984) was approved by the institutional review board, and written informed consent was obtained from all subjects. HV underwent repeat pCASL evaluations 2-4 weeks apart between November 2021 and October 2022. Patients with GBM were recruited for longitudinal MRI from September 2019 to February 2023. Intrasession repeatability (HV and GBM) and intersession reproducibility (HV only) of pCASL were assessed using linear regression, Bland-Altman analyses, the intraclass correlation coefficient (ICC) with 95% CI, and within-subject coefficients of variation (wsCV).
resultsTwenty HV (9 men; mean age, 25.1 [SD, 1.7] years; range, 23-30 years) and 21 patients with GBM (15 men; mean age, 59.8 [SD, 14.3] years; range, 28-81 years) were enrolled. In imaging sessions, 3D pCASL-measured perfusion with TSE-CASPR and GRASE, respectively, achieved high
conclusionsOur study demonstrated excellent intrasession repeatability of 3D pCASL-measured cerebral perfusion in HV and patients with GBM and good-to-excellent intersession reproducibility in HV. 3D pCASL with GRASE performed slightly better than 3D pCASL with TSE-CASPR in HV; however, in patients with GBM, 3D pCASL with TSE-CASPR showed better performance in tumor regions with a nearly 2-fold higher SNR. ASL-measured perfusion could serve as a noncontrast quantitative imaging biomarker to facilitate the management of patients with GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.